BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 30, 2007
 |  BioCentury  |  Strategy

Selling its pie by the slice

As it moves molecules from its neuronal nicotinic receptor platform through R&D, Targacept Inc. has been slicing off pieces that need bigger partners to develop, while using the money from these deals to support the area it's keeping, which currently is focused on depression and anxiety.

Last week, TRGT partnered its pain products with GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.) and granted the pharma access to other discovery programs across five therapeutic areas: pain, smoking cessation, obesity, addiction and Parkinson's disease.

"Pain is a different kind of business than the rest of the central nervous system indications, because traditionally people have struggled with turning preclinical efficacy into clinical efficacy since the mechanism is different. Also, the development and regulatory process is complex," J. Donald deBethizy, president & CEO, told BioCentury. "We needed experience and GSK is the ideal partner for this complex indication."

The deal includes TC-2696, a nicotinic acetylcholine...

Read the full 758 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >